Dyne therapeutics logo png
WebFeb 9, 2024 · 1 to 50 Employees. Founded: 2024. Type: Company - Public (DYN) Industry: Biotech & Pharmaceuticals. Revenue: Less than $1 million (USD) Competitors: Unknown. WebMar 20, 2024 · Dyne links therapeutic payloads to its TfR1-binding fragment antibody (Fab) to develop targeted therapeutics for muscle diseases. About DYNE-101 and the ACHIEVE Trial. DYNE-101 is an investigational therapeutic being evaluated in the Phase 1/2 global ACHIEVE trial, for people living with myotonic dystrophy type 1 (DM1).
Dyne therapeutics logo png
Did you know?
WebMar 24, 2024 · Dyne Therapeutics Inc Registered Shs's market capitalization is $642.40 M by 56.34 M shares outstanding. Dyne Therapeutics Stock Snapshot. ... Logos Global … WebWho invested in Dyne Therapeutics? Dyne Therapeutics has 9 investors including Logos Capital and Wellington Management. How much funding has Dyne Therapeutics raised to date? Dyne Therapeutics has raised $333M. When was the last funding round for Dyne Therapeutics? Dyne Therapeutics closed its last funding round on Jan 21, 2024 from a …
WebNov 3, 2024 · Cash position: Cash, cash equivalents and marketable securities were $248.1 million as of September 30, 2024, which is anticipated to fund operations through 2024. Research and development (R&D) expenses: R&D expenses were $34.7 million for the quarter ended September 30, 2024, compared to $36.5 million for the quarter ended … WebMar 24, 2024 · Dyne Therapeutics Inc Registered Shs's market capitalization is $642.40 M by 56.34 M shares outstanding. Dyne Therapeutics Stock Snapshot. ... Logos Global Management LP: 4.12:
WebAug 10, 2024 · Dyne Therapeutics today announced the closing of a $115 million equity financing led by new investors Vida Ventures and Surveyor Capital. Contacts Stephanie Simon Ten Bridge Communications (617 ... WebThe 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Dyne Therapeutics Inc 50-day moving average is $12.61.
WebApr 3, 2024 · Catherine Stehman-Breen, M.D., Dyne’s chief medical officer, held senior leadership roles at Amgen and Regeneron Pharmaceuticals, and most recently served …
WebSep 6, 2024 · Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy August … give the empirical formula of h2o2WebJan 20, 2024 · Dyne is developing a broad portfolio of therapeutics for muscle diseases, including programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy … give the electronic configuration of x 2−WebMar 20, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary ... give thee the desires of thine heartWebDyne Therapeutics is a biotechnology company which offers targeted therapies for patients with cardiac diseases, and serious and smooth muscle diseases. The Company … fusion 360 sharing projectsWebMay 16, 2024 · DYNE-101 is designed to enable targeted delivery to muscle tissue and address the genetic basis of the disease. The new data being presented during ASGCT … fusion 360 share files editingWebDyne Therapeutics. 239 likes · 14 talking about this. Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing … fusion 360 sheet metal bendWebDyne Therapeutics Information. Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in ... give the electronic configuration of lithium